PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT05654181
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 624
- Registration Number
- NCT05654623
- Locations
- 🇺🇸
Morton Plant Hospital - BayCare Health System, Clearwater, Florida, United States
🇺🇸3T Radiology LLC, Coconut Creek, Florida, United States
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States
A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men
- Conditions
- Healthy Participants
- Interventions
- Drug: Oral [14C]PF-07081532Drug: Oral PF-07081532 and IV [14C]PF-07081532
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT05652647
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05652660
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT05650333
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05650476
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
- Conditions
- Thromboembolism
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10000
- Registration Number
- NCT05643885
- Locations
- 🇺🇸
Pfizer Investigational, New York, New York, United States
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT05639647
- Locations
- 🇹🇷
Cukurova Universty, Sarçam, Adana, Turkey
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York, United States
Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children
- Conditions
- Lyme Disease
- Interventions
- Other: Normal Saline
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3235
- Registration Number
- NCT05634811
- Locations
- 🇺🇸
Velocity Clinical Research, Vestal, Vestal, New York, United States
🇺🇸UAB Child Health Research Unit (CHRU), Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States
Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT05630976
- Locations
- 🇨🇳
Zibo Central Hospital, Zibo, Shandong, China
🇨🇳The First Affiliated Hospital of USTC, Anhui Province Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China